Dr. Luo joined HematoLogics as the Director of Molecular Analysis in 2022. He is board certified by the American Board of Medical Genetics and Genomics in Clinical Molecular Genetics and Clinical Cytogenetics. He is a fellow of the American College of Medical Genetics and Genomics. Dr. Luo received his Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University, followed by a Leukemia & Lymphoma Society Postdoctoral Fellowship with Dr. Harvey Lodish at Whitehead Institute for Biomedical Research. He was a group leader at the Broad Institute of MIT and Harvard, the Director of Molecular Diagnostics Laboratory at Fox Chase Cancer Center, an NCI Comprehensive Cancer Center, and a Clinical Molecular Geneticist of Cancer Genomics at BioReference Laboratories, before joining HematoLogics. Dr. Luo has expertise in signal transduction, functional genomics, hematopoietic stem cells, clinical molecular genetics, Next-Generation Sequencing, and informatics.